# Phase-targeted erythropoietin derivatives for traumatic brain injury: bridging mechanisms to precision therapy

## TL;DR

This paper reviews modified forms of erythropoietin that may protect the brain after injury by targeting specific injury phases without causing harmful side effects.

## Contribution

The paper introduces phase-targeted erythropoietin derivatives that selectively activate protective pathways while avoiding erythropoietic and thrombotic effects.

## Key findings

- Engineered EPO derivatives like carbamylated EPO and HBSP preferentially activate PI3K–AKT over JAK2–STAT5 pathways.
- Meta-analyses suggest possible short-term mortality reduction but no consistent functional benefit or thrombotic risk.
- Each derivative is proposed to be effective in specific injury time windows based on mechanistic and experimental data.

## Abstract

Traumatic brain injury (TBI) unfolds through a well-defined chronology—hyperacute excitotoxic and inflammasome bursts, acute apoptotic and blood–brain-barrier failure, and subacute neurovascular remodeling—that no single-pathway drug can adequately cover. Recombinant erythropoietin (EPO) limits secondary damage in animals, yet its erythropoietic drive and thrombotic liability have stalled clinical adoption. This review integrates structural biology, pharmacology and translational data on four engineered EPO derivatives—carbamylated EPO, asialo-EPO, darbepoetin alfa and the helix-B surface peptide (HBSP/cibinetide)—that decouple cytoprotection from red-cell stimulation. We first outline how specific modifications (carbamylation, desialylation, hyper-glycosylation or helix truncation) bias EPOR signaling toward PI3K–AKT and away from JAK2–STAT5. We then match each derivative to its optimal injury window. Meta-analyses of randomized trials suggest a possible trend toward lower short-term mortality without a consistent functional benefit or thrombotic signal. By integrating molecular mechanisms, experimental findings, and early clinical observations, this review outlines hypotheses and future trial frameworks for phase-targeted, erythropoietin-based neuroprotection. Further controlled studies are required to establish safety, efficacy, and optimal therapeutic timing before translation to routine clinical use.